Table 3 Top 15 pathways, their corresponding number of genes and miRNAs, observed to be affected by the main CNAs, in the two groups of breast cancer patients analyzed (presented by the number of affected miRNAs).
From: Frequency of the TP53 R337H variant in sporadic breast cancer and its impact on genomic instability
R337H+ breast cancer patient | |||
|---|---|---|---|
KEGG pathway | #MiRNAs | #Genes | P value |
Pathways in cancer | 82 | 318 | 8.80E−04 |
Proteoglycans in cancer | 79 | 171 | 1.24E−02 |
Hippo signaling pathway | 77 | 125 | 1.57E−06 |
Focal adhesion | 76 | 175 | 5.28E−05 |
Signaling pathways regulating pluripotency of stem cells | 76 | 122 | 6.29E−03 |
Oxytocin signaling pathway | 72 | 132 | 6.95E−06 |
Axon guidance | 72 | 111 | 6.29E−03 |
TGF-beta signaling pathway | 67 | 70 | 5.28E−05 |
ErbB signaling pathway | 66 | 79 | 2.55E−05 |
Renal cell carcinoma | 65 | 62 | 2.47E−04 |
Pancreatic cancer | 62 | 59 | 4.95E−06 |
Glioma | 62 | 57 | 1.57E−06 |
ECM-receptor interaction | 62 | 70 | 6.29E−03 |
Colorectal cancer | 60 | 57 | 4.51E−06 |
Long-term depression | 60 | 51 | 2.08E−03 |
p53 signaling pathway | 55 | 60 | 2.56E−02 |
R337H− breast cancer patient | |||
|---|---|---|---|
KEGG pathway | #MiRNAs | #Genes | P value |
Proteoglycans in cancer | 10 | 65 | 1.74E−03 |
Hippo signaling pathway | 10 | 44 | 4.30E−03 |
Ras signaling pathway | 10 | 69 | 6.19E−03 |
Signaling pathways regulating pluripotency of stem cells | 10 | 40 | 5.23E−02 |
Pathways in cancer | 10 | 97 | 8.69E−02 |
Axon guidance | 10 | 38 | 1.84E−01 |
Focal adhesion | 10 | 59 | 1.84E−01 |
Thyroid hormone signaling pathway | 10 | 31 | 1.84E−01 |
ErbB signaling pathway | 9 | 34 | 6.29E−06 |
Regulation of actin cytoskeleton | 9 | 64 | 5.23E−02 |
Amphetamine addiction | 9 | 21 | 4.30E−03 |
Glioma | 8 | 26 | 5.13E−06 |
Lysine degradation | 8 | 16 | 6.29E−06 |
Renal cell carcinoma | 7 | 24 | 7.33E−02 |
Synaptic vesicle cycle | 6 | 18 | 2.27E−01 |
